NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

核因子kappa B激酶次单元β抑制剂:开发中产品分析

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品编码 408759
出版日期 内容资讯 英文 38 Pages
订单完成后即时交付
价格
核因子kappa B激酶次单元β抑制剂:开发中产品分析 Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2019
出版日期: 2019年12月27日内容资讯: 英文 38 Pages
简介

本报告提供以核因子kappa B激酶次单元β抑制剂为标的治疗药之开发平台现状及最新更新的各开发阶段比较分析,提供你涵括最新的新闻和发表之企业和研究机关开发中的治疗药,治疗药评估,后期阶段及中止的计划等相关资讯。

简介

  • 调查范围

核因子kappa B激酶次单元β抑制剂 概要

治疗药的开发

  • 开发中的产品:各开发阶段
  • 开发中的产品:各治疗领域
  • 开发中的产品:不同症状

开发中产品概况

  • 初期阶段的产品

企业开发中的产品

大学/机关开发中的产品

治疗药的评估

  • 单剂/并用治疗药的情况
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • 第一三共
  • EntreChem, S.L.
  • IMMD Inc.

药物简介

暂停中的计划

开发中止的产品

主要消息及新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC1986TDB

Summary

According to the recently published report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2019'; Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Inhibitor of nuclear factor kappa-B kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. Free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis.

The report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2019' outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Gastrointestinal which include indications Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Inflammatory Bowel Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer and Solid Tumor.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
  • The report reviews Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Overview
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development
  • EntreChem SL
  • IMMD Inc
  • Theralogics Inc
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Drug Profiles
  • 13-197 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EC-70124 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMD-0560 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit IKBKB for Inflammatory Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit IKBKB for Inflammation and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TLX-1423 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Dormant Products
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Discontinued Products
  • Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 17, 2018: EntreChem reports potent activity of EC-70124 in Acute Myeloid Leukemia
  • Mar 10, 2016: EntreChem's orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer
  • Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer
  • Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer
  • Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer
  • Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kinase Inhibitor EC-70124 At 2013 AACR Annual Meeting
  • Mar 26, 2012: EntreChem's Kinase Inhibitor Shows Potential For Treatment Of Head And Neck Cancer
  • May 09, 2011: EntreChem's Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by EntreChem SL, H2 2019
  • Pipeline by IMMD Inc, H2 2019
  • Pipeline by Theralogics Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019